Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871426 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53POLBCTDSP1TDP1 | |
| SCHEMBL289021 | 0.69 | — | — | |
| SCHEMBL15206083 | 0.69 | — | — | |
| SCHEMBL7976686 | 0.69 | — | — | |
| SCHEMBL29663753 | 0.66 | — | — | |
| SCHEMBL4269106 | 0.66 | — | — | |
| SCHEMBL6573461 | 0.66 | — | — | |
| SCHEMBL18871452 | 0.65 | TP53 (0.42) | SMN1; SMN2TP53POLBCTDSP1TDP1 | |
| SCHEMBL955853 | 0.65 | SMN1; SMN2 (0.57) | SMN1; SMN2TP53POLBCTDSP1TDP1 | |
| SCHEMBL18871416 | 0.65 | ALDH1A1 (0.46) | TP53POLBL3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| CN-111108083-B | Use of aminomethylene cyclohexane 1, 3-dione compounds | 微境生物医药科技(上海)有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-111108083-B | Use of aminomethylene cyclohexane 1, 3-dione compounds | 微境生物医药科技(上海)有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-111108083-B | Use of aminomethylene cyclohexane 1, 3-dione compounds | 微境生物医药科技(上海)有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
| CN-111108083-A | Use of aminomethylene cyclohexane 1, 3-dione compounds | 微境生物医药科技(上海)有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111108083-A | Use of aminomethylene cyclohexane 1, 3-dione compounds | 微境生物医药科技(上海)有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2018214814-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | 苏州偶领生物医药有限公司 | 2018-11-29 | — | — | WO | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | ATG7, BECN1, SQSTM1 | SMN1; SMN2 1875/4885TP53 2049/4885POLB 4228/4885 |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | ATG7, BECN1, SQSTM1 | SMN1; SMN2 1875/4885TP53 2049/4885POLB 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.